Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Prophylactic acid suppressants in children in the intensive care unit: a systematic review with meta-analysis and trial sequential analysis

Publikation: Bidrag til tidsskriftReviewpeer review


  1. Lower or Higher Oxygenation Targets for Acute Hypoxemic Respiratory Failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Preferences for the measurement and supplementation of magnesium, phosphate and zinc in ICUs: The international WhyTrace survey

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Developing and validating COVID-19 adverse outcome risk prediction models from a bi-national European cohort of 5594 patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Correction to: Is the literature inconclusive about the harm from HES? No

    Publikation: AndetAndet bidragForskning

Vis graf over relationer

BACKGROUND: Critically ill children are at risk of stress-induced gastrointestinal ulceration. Acid suppressants are frequently used in intensive care units even though there is uncertainty about the benefits and harms. With this systematic review, we aimed to assess patient-important benefits and harms of stress ulcer prophylaxis (SUP) in children in intensive care.

METHODS: We conducted the review according to the PRISMA statement, the Cochrane Handbook, and GRADE, using conventional meta-analysis and trial sequential analysis (TSA). We included randomised clinical trials comparing SUP with histamine-2-receptor antagonists or proton pump inhibitors vs placebo/no prophylaxis in children admitted for intensive care. Primary outcomes were all-cause mortality and overt gastrointestinal bleeding. Secondary outcomes were serious adverse events, hospital-acquired pneumonia, Clostridium difficile enteritis, myocardial ischemia, acute kidney injury and quality of life.

RESULTS: We included a total of seven trials (n = 504) with eight trial comparisons. We found no statistically significant difference in all-cause mortality (relative risk (RR) 1.43, 95% confidence interval (CI) 0.86-2.37), overt gastrointestinal bleeding (RR 0.75, 95% CI 0.42-1.35) or hospital-acquired pneumonia (RR 1.18, 95% CI 0.77-1.82) between SUP vs placebo/no prophylaxis. No trials reported on remaining secondary outcomes. TSA was unable to draw firm conclusions for all outcomes and certainty of evidence for all outcomes was "very low."

CONCLUSIONS: We found no difference in all-cause mortality, overt gastrointestinal bleeding or hospital-acquired pneumonia in children in intensive care receiving acid suppressants compared with placebo/no prophylaxis. However, the quantity and quality of evidence was very low with no firm evidence for benefit or harm.

TidsskriftActa Anaesthesiologica Scandinavica
Udgave nummer3
Sider (fra-til)292-301
Antal sider10
StatusUdgivet - mar. 2021

ID: 61231837